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Background: Using genetic scores for fasting plasma glucose (FPG 
GS) and type 2 diabetes (T2D GS), we investigated whether the fasting, 
1-hour and 2-hour glucose thresholds from the WHO 2013 criteria for 
gestational diabetes (GDM) have different implications for genetic 
susceptibility to raised fasting glucose and type 2 diabetes in women 
from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) and 
Atlantic Diabetes in Pregnancy (DIP) studies. 
Methods: Cases were divided into three subgroups: (i) FPG ≥5.1 
mmol/L only, n=222; (ii) 1-hour glucose post 75 g oral glucose load ≥10 
mmol/L only, n=154 (iii) 2-hour glucose ≥8.5 mmol/L only, n=73; and 
(iv) both FPG ≥5.1 mmol/L and either of a 1-hour glucose ≥10 mmol/L 
or 2-hour glucose ≥8.5 mmol/L, n=172. We compared the FPG and T2D 
GS of these groups with controls (n=3,091) in HAPO and DIP separately. 
Results: In HAPO and DIP, the mean FPG GS in women with a FPG 
≥5.1 mmol/L, either on its own or with 1-hour glucose ≥10 mmol/L or 
2-hour glucose ≥8.5 mmol/L, was higher than controls (all P <0.01). 
Mean T2D GS in women with a raised FPG alone or with either a raised 
1-hour or 2-hour glucose was higher than controls (all P <0.05). GDM 
defined by 1-hour or 2-hour hyperglycaemia only was also associated 
with a higher T2D GS than controls (all P <0.05). 
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Conclusions: The different diagnostic categories that are part of the 
WHO 2013 criteria for GDM identify women with a genetic 
predisposition to type 2 diabetes as well as a risk for adverse 
pregnancy outcomes.
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Introduction
Gestational diabetes mellitus (GDM) has been variably defined 
since criteria were first developed over 50 years ago1. The 
World Health Organization (WHO) introduced diagnostic cri-
teria for GDM in 1999, based on criteria for overt diabetes in 
the general population, with a fasting plasma glucose (FPG) 
≥7.0 mmol/L or impaired glucose tolerance with a 2-hour 
glucose >=7.8 mmol/L post 75 g oral glucose load as part of 
an oral glucose tolerance test (OGTT), measured between 24 
and 28 weeks gestation2. However, lesser degrees of maternal 
fasting hyperglycaemia have long been associated with a higher 
risk for adverse perinatal outcomes3, so a FPG ≥6.1 mmol/L 
(indicative of impaired fasting glycaemia in the non-pregnant 
population4) was also integrated into the WHO criteria.
The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) 
Study5 followed 23,316 women who underwent a 2-hour OGTT 
between 24 and 32 weeks gestation throughout pregnancy 
and found a continuous association between maternal glucose 
values and adverse perinatal outcomes, including birth weight 
≥90th centile (large for gestational age, LGA) and primary 
caesarean section. In 2010, the International Association of 
Diabetes and Pregnancy Study Groups (IADPSG) determined 
cut-off values equivalent to 1.75 times the odds for adverse 
pregnancy outcomes at mean glucose values, resulting in 
diagnostic thresholds for FPG ≥5.1 mmol/L, 1-hour glucose 
≥10 mmol/L and 2-hour glucose ≥8.5 mmol/L6.
WHO adopted the recommendations of IADPSG in 20132, which 
has resulted in a higher number of cases identified as GDM 
due to the lower FPG threshold (estimated up to 17.8% preva-
lence of GDM for IADPSG 2010 criteria6 vs 9.4% prevalence 
for WHO 1999 criteria7). Whilst these thresholds were chosen 
for their Obstetric risks, the HAPO Follow-Up Study found that 
women diagnosed by the newer criteria have a higher risk of 
developing disorders of glucose metabolism, including T2D, 
10 years after the episode of GDM8. A proportion of this risk 
can be attributed to genetic predisposition, since genome wide 
association study (GWAS) data from large, non-pregnant 
population-based studies have identified multiple loci associ-
ated with FPG9 and type 2 diabetes10 and some of these are 
shared with GDM11–16. Specific to the WHO 2013 criteria, sin-
gle nucleotide polymorphisms (SNPs) at the GCK and TCF7L2 
loci were shown to be associated with FPG and 2-hour glucose 
levels post-OGTT in women with GDM17. In addition, genetic 
risk scores for glycaemic traits, including FPG and type 
2 diabetes, have been associated with a higher odds for GDM 
according to the WHO 2013 criteria18. However, it is not 
known whether the underlying genetic predisposition to fast-
ing hyperglycaemia and type 2 diabetes varies depending on 
how the diagnosis of GDM is met.
The objective of this study was to investigate whether there 
is a difference in genetic risk for fasting hyperglycemia and 
type 2 diabetes according to the different diagnostic thresholds 
of glucose tolerance from the WHO 2013 criteria for GDM. 
To do this, we used a genetic score (GS) for FPG (FPG GS) or 
T2D (T2D GS) (consisting of previously-identified loci9,19)  
Methods
Study population
Women of European ancestry (self-reported white ethnicity) 
with singleton pregnancies and without known pre-existing 
diabetes from the Hyperglycemia and Adverse Pregnancy 
Outcome (HAPO) Study5 (n=2,628) and Atlantic Diabetes in 
Pregnancy (DIP) study20 (n=1,084) were included. The HAPO 
study was an observational, multi-centre study (N=23,316 
participants from 15 centres) to which women were recruited 
during pregnancy if they were over 18 years of age5. The 2,665 
European-ancestry participants included in the current study 
were those with genotype data available on selected SNPs (see 
below). The DIP study had a case-control design: approximately 
three genotyped control participants without GDM (defined 
initially as a maternal FPG <5.6 mmol/L and/or 2-hour glucose 
post oral glucose load <7.8 mmol/L) were available for every 
genotyped case participant included in our analyses. 
Sample collection and clinical characteristics
The study methods used in HAPO and DIP have been described 
in detail previously5,7,20–22. Maternal FPG in mmol/L was meas-
ured prior to a standard 2-hour OGTT with 75 g of glucose 
between 24 and 32 weeks in HAPO and 24 and 28 weeks in 
DIP. Information on maternal age, pre-pregnancy body mass 
index (BMI) and systolic blood pressure (SBP, in mmHg) was 
collected at the OGTT appointment. Clinical characteristics of 
participants in HAPO and DIP with and without GDM were 
different (women in DIP were older, had a higher BMI and 
higher SBP, all P <0.01), hence clinical characteristics (where 
available) have been presented separately.
GDM diagnostic criteria subgroups
We used the WHO 2013 cut-offs (previously IADPSG 2010) 
to define fasting and 2-hour hyperglycaemia. Thus, in the 
          Amendments from Version 2
We would like to thank all of the reviewers for their time in 
reviewing the second version of the manuscript and providing 
additional comments to help further improve the work.
We have responded to each of the reviewers’ points in detail. 
The following summarises the changes made to Version 2 of the 
manuscript:
We have clarified the source of effect sizes (Betas) for the T2D GS 
and added additional information on effect allele frequencies for 
proxies and how linkage disequilibrium was calculated in Table 1 
and Table 2. We have given an indicative calculation of power of 
the samples to detect associations between FPG and the FPG GS 
in the Methods section. We have added the mean and SD FPG 
and T2D GS for the different groups to Table 3. We have removed 
the multiple instances of mmol/l in Table 4. We have confirmed 
that sensitivity analyses adjusting for maternal BMI and age did 
not affect the relationships between GSs and GDM diagnostic 
categories in the Results section. We have added additional 
information to the Discussion section describing the possible 
implications of small sample sizes and power, why we did not 
meta-analyse the results from both studies and the possibility of 
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current study, women diagnosed with GDM were divided into 
fasting hyperglycaemia only (FPG ≥5.1 mmol/L and 1-hour and 
2-hour glucose post 75 g oral glucose load <10 mmol/L and 
<8.5 mmol/L, respectively, n=222), elevated 1-hour glucose only 
(1-hour glucose ≥10 mmol/l, FPG <5.1 mmol/L and 2-hour 
glucose <8.5 mmol/l, n=154), elevated 2-hour glucose only 
(2-hour glucose ≥8.5 mmol/L, FPG <5.1 mmol/L and 1-hour 
glucose <10 mmol/L , n=73) and both (FPG ≥5.1 mmol/L and 
either a 1-hour glucose ≥10 mmol/L or 2-hour glucose 
≥8.5 mmol/L, or both, n=172) subgroups Figure 1. Women 
without GDM were defined as having FPG <5.1 mmol/L, 1-hour 
glucose <10 mmol/L and 2-hour glucose <7.8 mmol/L (n=3,091). 
The distributions of the women in the different groups and in 
each of the study cohorts are shown in Figure 1.
Genotyping
Genotyping of individual SNPs in DNA samples from both 
the DIP and HAPO studies was carried out at LGC Genomics 
(Hoddesdon, UK), using the PCR-based KASPTM genotyping assay. 
We first selected 41 SNPs that had been previously associated 
with type 2 diabetes, and 16 SNPs associated with fasting 
glucose in non-pregnant individuals, for genotyping in the DIP 
study. Overlap between the type 2 diabetes and FPG SNPs 
meant that seven FPG loci were also in the list of type 2 diabetes 
loci. The median genotyping call rate in the DIP samples was 
0.992 (range 0.981–0.996), and there was >99% concordance 
between duplicate samples (8% of total genotyped samples were 
duplicates). We excluded one FPG SNP and one type 2 diabetes 
SNP that showed deviation from Hardy-Weinberg Equilibrium 
(Bonferroni-corrected P value <0.05). For details of included 
and excluded SNPs and their sources, see Table 1 and 
Table 2.
In the HAPO study, we selected SNPs from the same 16 FPG 
and 41 type 2 diabetes loci for genotyping in women of European 
ancestry with DNA available. The selection and genotyping 
of SNPs in the HAPO study was performed at different times 
from that in the DIP study. Owing to the differing avail-
ability of published GWAS results at these times, the genotyped 
SNPs differed between HAPO and DIP at 9 of the associated 
loci. The HAPO SNPs at the nine loci were generally well 
correlated with those genotyped in DIP (r2 >0.7, apart from at 
the ADAMTS9 locus where r2 = 0.45). The median genotyping 
call rate in the HAPO samples was 0.984 (range 0.955–0.991), 
and the mean concordance between duplicate samples was 
>98.5% (at least 1% of samples were duplicated). We excluded 
one SNP that showed deviation from Hardy-Weinberg 
Equilibrium in the HAPO study (Bonferroni-corrected P value 
<0.05; see Table 1 and Table 2). After exclusion of SNPs 
that showed deviation from Hardy-Weinberg equilibrium and 
one SNP from the type 2 diabetes score whose main effect 
was on BMI (rs11642841 (FTO locus)23, a total of 15 SNPs at 
FPG-associated loci and 38 SNPs at type 2 diabetes-associated 
loci were available in both studies for analysis.
Figure  1. Distribution of participants diagnosed with gestational diabetes (GDM) by different glucose categories in 
Hyperglycemia  and  Adverse  Pregnancy  Outcome  Study  (HAPO)  and  Atlantic  Diabetes  in  Pregnancy  Study  (DIP). All glucose 
values are in mmol/L. The 1-hour and 2-hour glucose measures refer to the glucose level measured at 1 and 2 hours, respectively, following 
a 75 g oral glucose load as part of an oral glucose tolerance test. Women with a FPG ≥5.1 mmol/L and either a 1-hour glucose ≥10 mmol/L 
or 2-hour glucose ≥8.5 mmol/L, or both, were combined as one group for analyses.
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1:214159256 rs340874 PROX1 C/T 0.57 0.013
2:27741237 rs780094 GCKR C/T 0.62 0.029



















8:118184783 rs13266634 SLC30A8 C/T 0.69 0.027
9:4289050 rs7034200 GLIS3 A/C 0.48 0.018
10:114758349 rs7903146 TCF7L2 T/C 0.29 0.023
11:45873091 rs11605924 CRY2 A/C 0.48 0.015
11:47336320 rs7944584 MADD A/T 0.72 0.021
11:61571478 rs174550 FADS1 T/C 0.65 0.017
11:92708710 rs10830963 MTNR1B G/C 0.28 0.067
15:62433962 rs11071657 C2CD4B A/G 0.62 0.008
SNP, single nucleotide polymorphism. aProxy SNPs were genotyped and analysed in the Hyperglycemia 
and Adverse Pregnancy Outcome Study (both r2 > 0.85 in 340,000 British white unrelated samples 
from Version 3 release of UK Biobank24, calculated using PLINK software25). bEffect allele frequency was 
calculated in 340,000 British white unrelated samples from the UK Biobank24. cBeta values were aligned 
to the trait-raising allele on the + strand (Human Genome Assembly Reference hg19). Source of SNPs and 
beta values: Dupuis et al., 20109. We used the same Beta values for proxy SNPs. We excluded rs10885122 
(ADRA2A locus) due to deviation from Hardy-Weinberg Equilibrium in the Atlantic Diabetes In Pregnancy 
Study (Bonferroni corrected P < 0.05).
Generating a genetic score for FPG and type 2 diabetes
Weighted genetic scores for FPG (FPG GS) and type 2 
diabetes (T2D GS) were generated using the 15 SNPs and 
38 SNPs, respectively. All weights for the FPG GS and 
T2D GS were taken from Dupuis et al.9 and Voight et al.26, 
respectively. The GSs were calculated by taking the sum 
of the number of FPG-raising or type 2 diabetes risk alleles 
(0, 1 or 2) for each SNP, multiplied by its corresponding beta 
value (effect size, see Table 1 and Table 2) for association 
with FPG or type 2 diabetes, divided by the sum of all beta 
values and multiplied by the total number of SNPs analysed 
(see Figure 2 for formula). GS were generated for participants 
with complete data for all included SNPs only.
Statistical analyses
Analysis of clinical characteristics. Clinical characteristics were 
compared between participants with and without GDM in 
HAPO and DIP using unpaired t-tests for normally distributed 
data and the Wilcoxon Rank-Sum test for non-normally distributed 
data. P values were corrected for 24 comparisons using the 
Bonferroni method.
Analysis of associations between FPG GS or T2D GS with 
glucose levels and GDM. Associations of the FPG GS or T2D 
GS with FPG, 1-hour and 2-hour glucose in women with and 
without GDM (cases and controls) were analysed using lin-
ear regression in HAPO (which was a representative sample of 
European participants from the whole study cohort) and 
DIP. P values were corrected for 24 comparisons using the 
Bonferroni method. Our sample of N=2,628 HAPO and 
N=1,084 DIP participants both provided 100% power to detect 
associations between fasting glucose levels and the fasting 
glucose GS at α=0.002, assuming the GS explains 6% vari-
ance in glucose levels, which was estimated in 849 pregnant 
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Table 2. Thirty-eight SNPs associated with type 2 diabetes (T2D) risk and used to construct the T2D genetic score.






1:120526982 rs1493694 NOTCH2 T/C 0.11 0.110 Zeggini et al., 200827
1:214163675 rs340835 PROX1 A/G 0.49 0.062 Dupuis et al., 20109
2:27741237 rs780094 GCKR C/T 0.62 0.011 Dupuis et al., 20109
2:43732823 rs7578597 THADA T/C 0.89 0.141 Zeggini et al., 200827







0.083 Rung et al., 200928
3:12393125 rs1801282 PPARG C/G 0.88 0.138 Altshuler et al., 200029














0.097 Dupuis et al., 20109
4:6292915 rs10010131 WFS1 G/A 0.60 0.104 Sandhu et al., 200731







0.170 Zeggini et al., 200732














0.099 Kong et al., 200933
8:95937502 rs7845219 TP53INP1 T/C 0.50 0.093 Voight et al., 20104
8:118184783 rs13266634 SLC30A8 C/T 0.69 0.139 Sladek et al., 200734
9:22133284 rs10965250 CDKN2A/B G/A 0.83 0.181 Zeggini et al., 200732









0.088 Zeggini et al., 200827
10:94465559 rs5015480 HHEX/IDE C/T 0.59 0.166 Zeggini et al., 200732
10:114758349 rs7903146 TCF7L2 T/C 0.29 0.335 Grant et al., 200635
11:1696849 rs2334499 HCCA2/
DUSP8
T/C 0.42 0.080 Kong et al., 200933
11:2691471 rs231362 KCNQ1 G/A 0.52 0.104 Kong et al., 200933
11:2847069 rs163184 KCNQ1 G/T 0.48 0.083 Yasuda et al., 200836, Unoki 
et al., 200837
11:17408630 rs5215 KCNJ11 C/T 0.36 0.089 Gloyn et al., 200338







0.115 Prokopenko et al., 200939, 
Dupuis et al., 20109
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12:66170163 rs2612067 HMGA2 G/T 0.10 0.180 Voight et al., 201026
12:71613276 rs1353362 TSPAN8/ 
LGR5







0.112 Voight et al., 201026
13:80717156 rs1359790 SPRY2 G/A 0.71 0.096 Shu et al., 201040
15:62396389 rs7172432 C2CD4A/B A/G 0.57 0.068 Yamauchi et al., 201030
15:77747190 rs7178572 HMG20A G/A 0.71 0.068 Kooner et al., 201141
15:80432222 rs11634397 ZFAND6 G/A 0.66 0.102 Voight et al., 201026
17:36098040 rs4430796 HNF1B G/A 0.48 0.130 Gudmundsson et al., 200742
X:152908152 rs2301142 DUSP9 A/G 0.85 0.086 Voight et al., 201026
SNP, single nucleotide polymorphism. aProxy SNPs were genotyped and analysed in the Hyperglycemia and Adverse Pregnancy Outcome Study  
(r2 > 0.7 in 340,000 British white unrelated samples from Version 3 release of UK Biobank24, except for at ADAMTS9 where r2 = 0.4524, calculated using 
PLINK software25). bEffect allele frequency was calculated in 340,000 British white unrelated samples from the UK Biobank24. cBeta values were aligned 
to the T2D-risk allele on the + strand (Human Genome Assembly Reference hg19). Beta value = log odds ratio for T2D from genome-wide association 
study meta-analysis of up to 8130 cases and 38987 controls, published in Voight et al. 201026. We used the same Beta value for proxy SNPs. We 
excluded rs8042680 (PRC1 locus, Atlantic Diabetes in Pregnancy Study) and rs1470579 (IGF2BP2 locus, Hyperglycemia and Adverse Pregnancy 
Outcome Study) from the T2D GS due to deviation from Hardy-Weinberg Equilibrium (Bonferroni-corrected P <0.05). We additionally excluded 
rs11642841 (FTO locus) due to its primary effect on BMI23.
Figure 2. Formula for generating a weighted genetic score (GS). “Number of alleles” corresponds to either the number of risk alleles 
(type 2 diabetes single-nucleotide polymorphisms (SNPs)) or the number of glucose-raising alleles (fasting plasma glucose SNPs).
individuals without diabetes in an external study (Exeter 
Family Study of Childhood Health (EFSOCH))43. Means for 
FPG GS and T2D GS in women with and without GDM were 
compared using unpaired t-tests in each study cohort sepa-
rately, as the genetic scores were higher overall in DIP. P values 
were Bonferroni corrected for 16 comparisons Sensitivity 
analyses adjusting GS for maternal pre-pregnancy BMI and 
age (where available) were performed using ANCOVA.
Statistical software. All statistical analyses were performed using 
Stata version 14.0 (StataCorp LP, College Station, TX, USA). 
P-values <0.05 were considered to indicate evidence of 
association, unless otherwise stated.
Ethics approval
Ethics approval was obtained from the Northwestern 
University Office for the Protection of Research Participants 
for HAPO (Protocol # 0353-001). The HAPO study protocol 
was approved by the institutional review board at each field 
center and all participants gave written, informed consent. Ethics 
approval was obtained from the local Galway University Hospital 
Research Ethics Committee for Atlantic DIP (Ref: 54/05) and all 
participants gave written, informed consent.
Results
Clinical characteristics in women with and without GDM
Clinical characteristics for women with and without GDM are 
summarised in Table 3 for HAPO and DIP, respectively. Women 
with a FPG ≥5.1 mmol/L (on its own or with either 1-hour 
or 2-hour hyperglycaemia) had a higher pre-pregnancy BMI than 
women without GDM in HAPO and DIP (P values <0.001). 
Women with both fasting and either 1-hour or 2-hour hypergly-
caemia were older compared with controls in HAPO (P value 
<0.05 after Bonferroni correction). In HAPO we observed a higher 
SBP for women diagnosed with GDM by a FPG ≥5.1 mmol/L 
only compared with controls (P value <0.001) and they had a 
higher SBP when either their 1-hour or 2-hour glucose was also 
raised, but the P value was >0.05 after Bonferroni correc-
tion. In DIP there was a higher SBP for women diagnosed by 
both fasting and either 1-hour or 2-hour hyperglycaemia cri-
teria compared with controls (P value <0.05 after Bonferroni 
correction).
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FPG, 1-hour and 2-hour glucose are associated with 
FPG and T2D GS in pregnant women with and without 
GDM
FPG, 1-hour and 2-hour glucose values were associated with 
the fasting and type 2 diabetes genetic scores in HAPO and DIP 
Table 4. Adjusting for the different measures of glucose toler-
ance suggested that these associations were not independent of 
one another.
Women diagnosed with GDM by fasting glucose criteria 
have a higher FPG GS
We observed a higher FPG GS in women diagnosed with GDM 
by fasting hyperglycaemia only and by both fasting and either 
1-hour or 2-hour criteria, compared with controls (Figure 3A, 
all P values for comparison with control group <0.05 after 
Bonferroni correction). There was also evidence that women 
with a raised 1-hour glucose only had a higher FPG GS in HAPO 
(P value for comparison with controls <0.01 but >0.05 with 
Bonferroni correction), but this was not as strong in DIP (P value 
=0.05). In contrast, women diagnosed with GDM by 2-hour 
only criteria did not have a higher FPG GS overall (P values for 
comparison with controls >0.05 in both studies). Sensitivity 
analyses adjusted for maternal BMI and age did not materially 
alter the GS relationships (Extended data Tables 1A and 1B).
Women diagnosed with GDM by fasting, 1-hour or 2-hour 
criteria have a higher T2D GS than controls
The T2D GS was higher than controls in women with fasting, 
1-hour or 2-hour hyperglycaemia in HAPO and DIP (Figure 3B): 
all P values for comparison with controls were <0.05 after 
correction except for the fasting and 1-hour only groups. As 
with the FPG GS, sensitivity analyses adjusted for maternal 
BMI and age did not materially affect the associations seen 
(Extended data Tables 1A and 1B).
Discussion and conclusions
In this study of 3,712 pregnant women of European ancestry, 
we have confirmed that women diagnosed with GDM according 
to the WHO 2013 criteria have a raised genetic risk for type 2 
diabetes and shown for the first time that this risk was raised 
across all of the different measures of glucose tolerance. A genetic 
predisposition to a higher FPG was present for women who 
met the fasting glucose criteria (and 1-hour glucose criteria in 
HAPO), but was not present for women who met the 2-hour 
criteria.
We confirmed that FPG in pregnant women both with and with-
out GDM was positively associated with a FPG GS generated 
using SNPs identified in a non-pregnant population9. The 1-hour 
and 2-hour glucose values were also correlated with the FPG 
GS, but this could potentially be explained by their associa-
tion with FPG, since this association was not as strong once 
this was taken into account. Thus, the observation that the FPG 
GS was not higher in women diagnosed with GDM due to a 
2-hour glucose ≥8.5 mmol/L alone was likely because these 
women did not have fasting hyperglycemia. However, larger 
sample sizes would be needed to confidently rule out differ-
ences in FPG GS between these groups. Maternal FPG was 
also associated with the T2D GS, which would be expected, 
as there are loci within the T2D GS which also raise fasting 
glucose (e.g. GCK, MTNR1B)9. The ADCY5 locus has also been 
found to be associated with 2-hour glucose values44. Thus, the 
observation of a higher T2D GS in women meeting the fasting or 






































































BMI, body mass index; DIP, Atlantic Diabetes in Pregnancy Study; FPG, fasting plasma glucose; HAPO, Hyperglycemia and Adverse Pregnancy Outcome 
Study; IQR, interquartile range; SBP, systolic blood pressure. aThe 1-hour and 2-hour glucose measures refer to the glucose level measured at 1 and 2 hours, 
respectively, following a 75 g oral glucose load as part of an oral glucose tolerance test. *P value <0.05 for comparison with controls (>0.05 after Bonferroni 
correction). **P value <0.05 for comparison with controls (<0.05 after Bonferroni correction). ***P value <0.001 for comparison with controls (remained 
<0.001 after Bonferroni correction).
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Beta coefficient (mmol/L) 
per one unit higher FPG 
GS (95% CI)





Beta coefficient (mmol/L) 
per one unit higher T2D 
GS (95% CI)




Fasting 0.028 (0.023-0.032)*** 0.022 (0.018-0.027)*** 0.008 (0.004-0.011)*** 0.003 (-3.8 x 10-4-0.006)
1-hrc 0.060 (0.040-0.081)*** 0.009 (-0.007-0.025) 0.051 (0.037-0.066)*** 0.019 (0.008-0.031)**




Beta coefficient (mmol/L) 
per one unit higher FPG 
GS (95% CI)





Beta coefficient (mmol/L) 
per one unit higher T2D 
GS (95% CI)




Fasting 0.050 (0.039-0.061)*** 0.030 (0.021-0.039)*** 0.016 (0.008-0.025)** -0.001 (-0.008-0.006)
1-hrc 0.136 (0.093-0.179)*** 0.034 (-9.35 x 10-6-0.067) 0.110 (0.079-0.141)*** 0.055 (0.030-0.078)***
2-hrc 0.071 (0.038-0.105)*** -0.015 (-0.042-0.011) 0.065 (0.041-0.089)*** 0.014 (-0.005-0.033)
CI, confidence interval; DIP, Atlantic Diabetes in Pregnancy Study; HAPO, Hyperglycemia and Adverse Pregnancy Outcome Study. aThese analyses were 
performed in HAPO as it was a representative sample of pregnant women of European ancestry. bAs ATLANTIC-DIP had a case-control design the beta 
coefficients will not be representative of the general pregnant population but are presented for comparison with HAPO. cThe 1-hour and 2-hour glucose 
measures refer to the glucose level measured at 1 and 2 hours, respectively, following a 75 g oral glucose load as part of an oral glucose tolerance test.  
** P value <0.001, <0.01 after Bonferroni correction. *** P value <0.001, remained <0.001 after Bonferroni correction.
for 1-hour glucose values was not available at the time of writ-
ing, but since we found the T2D GS to be associated with 1-hour 
glucose values in HAPO, it is likely that this explains the higher 
T2D GS seen in the women meeting this criterion for diagnosis 
of GDM, and will contribute to the higher T2D GS seen in 
women with both a fasting and either 1-hour or 2-hour hyperg-
lycaemia. However, it is important to note that the relationships 
between the T2D GS and the different glucose categories did 
not appear to be independent of one another, and again, 
although women meeting the diagnosis for GDM in one 
category may not meet the thresholds for GDM in other 
categories, they are likely to have a degree of fasting and 
postprandial hyperglycaemia which will contribute to their 
higher genetic risk for type 2 diabetes compared with women 
without GDM.
One might expect that women with both fasting and postprandial 
hyperglycaemia would have the highest genetic risk for type 2 
diabetes, but we did not observe this for the T2D GS in women 
with both a FPG ≥5.1 mmol/L and either a 1-hour glucose 
≥10 mmol/L or 2-hour glucose ≥8.5 mmol/L. On the whole, the 
relationship between GDM and a higher T2D GS was clearest 
for women with a raised 2-hour glucose or a combination of 
raised fasting and 1-hour or 2-hour glucose, but studies with 
greater statistical power will be needed to confirm whether genetic 
risk of T2D is heterogeneous across the different thresholds 
of glucose tolerance that are part of the WHO 2013 criteria 
for GDM.
Previous studies investigating the association between genetic 
risk scores for glycaemic traits and GDM have provided 
interesting insights into the biology of GDM. For example, 
in a study including women from HAPO as well as a Canadian 
cohort-study (Gen3G), a fasting glucose genetic risk score 
was strongly associated with FPG in pregnant women, explain-
ing a similar variance in FPG to the non-pregnant population18. 
Furthermore, genetic risk scores for insulin sensitivity and 
insulin secretion were associated with these traits in pregnancy, 
emphasising there to be an important shared genetic compo-
nent to these both in and outside of pregnancy. Several SNPs 
at risk loci included in the genetic scores for FPG and type 2 
diabetes risk in this study have previously been associated with 
GDM at genome-wide significance (CDKAL1, G6PC2, GCKR, 
MTNR1B14,45) and at lesser-degrees of significance (e.g. HNF1A, 
TCF7L2, HHEX/IDE, PPARG15,17,18,45). These loci have been 
implicated in diverse physiological processes influencing 
glucose metabolism, such as beta cell function and insulin 
secretion, and insulin resistance secondary to lipodystrophy 
and disrupted liver lipid metabolism46,47. Along with previous 
studies showing associations between GDM and genetic risk 
scores including SNPs at risk loci associated with type 2 
diabetes15,18, our study supports the growing evidence that 
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Figure 3. Plots showing mean fasting plasma glucose (FPG) (A) or type 2 diabetes (T2D) (B) genetic score (GS) in each gestational diabetes 
(GDM) glucose diagnostic category in the Hyperglycemia and Adverse Pregnancy Outcome Study (HAPO) and Atlantic Diabetes in Pregnancy 
Study (DIP). The 1-hour and 2-hour glucose groups refer to glucose levels measured at 1 and 2 hours, respectively, following a 75 g oral 
glucose load as part of an oral glucose tolerance test. The control group include women with a FPG <5.1 mmol/L, 1-hour glucose <10 
mmol/L and 2-hour glucose <8.5 mmol/L. The fasting only group includes women with a FPG ≥5.1 mmol/L, a 1-hour glucose <10 mmol/L 
and 2-hour glucose <8.5 mmol/L. The 1-hour only group includes women with 1-hour glucose ≥10 mmol/L, FPG <5.1 mmol/L and 2-hour 
glucose <8.5 mmol/L. The 2-hour only group includes women with a 2-hour glucose ≥8.5 mmol/L, FPG <5.1 mmol/L and 1-hour glucose <10 
mmol/L. The remaining group includes women with both a FPG ≥5.1 mmol/L and either a 1-hour glucose ≥10 mmol/L or 2-hour glucose 
≥8.5 mmol/L, or both. Error bars show 95% confidence intervals. *P value for comparison between cases and controls <0.05 **P value 
for comparison between cases and controls <0.01. ***P value for comparison between cases and controls <0.001. All P values survived 
Bonferroni correction at α=0.05 except for the FPG GS in women with 1-hour hyperglycaemia in HAPO and the T2D GS in women with 
isolated fasting or 1-hour hyperglycaemia in HAPO and DIP.
genetic determinants of glycaemic traits influence both of these 
phenotypes.
Although genetic predisposition will contribute to the underly-
ing pathophysiology of GDM, it explains only part of GDM 
risk. So far, models including genetic risk scores for glycaemic 
traits have shown limited predictive ability18,48, suggesting 
they may not be sufficiently accurate to be used on their own in 
determining who should be screened for GDM. Therefore, it is 
still important to consider other well established risk factors, 
such as parity, maternal age, BMI, ethnicity and socioeconomic 
background in stratifying risk of GDM5.
This work specifically examining the genetic risk of type 2 
diabetes in women diagnosed with GDM according to different 
measures of glucose tolerance supports the results from the 
recent HAPO Follow-Up Study8, which showed that women 
diagnosed with GDM post-hoc according to WHO 2013 
criteria had a higher risk for type 2 diabetes 10 to 14 years after 
pregnancy. We observed the highest BMIs in women diagnosed 
with GDM by fasting hyperglycaemia only or both criteria, 
which is consistent with previous research showing that women 
diagnosed with GDM by the WHO 2013 criteria were more 
overweight than those diagnosed by WHO 1996 criteria7,49. 
However, the associations seen for GDM with FPG GS and T2D 
GS are not driven by BMI (the genetic variants included within 
the scores do not primarily affect FPG and T2D risk because of 
an effect on BMI), suggesting that women with fasting hyper-
glycaemia in pregnancy are likely to have both BMI-related 
metabolic factors and a genetic predisposition contributing 
to type 2 diabetes risk. Furthermore, women with an isolated 
2-hour hyperglycaemia did not have a significantly higher BMI 
than controls, which could suggest a more important role for genetic 
predisposition in this group of women. However, non-genetic 
environmental factors related to development of type 2 diabe-
tes such as diet, exercise and socioeconomic deprivation remain 
a key consideration, as genetics will explain only a portion 
of risk for type 2 diabetes in women with a history of GDM. 
For example, a recent study of 2,434 women of white ethnic-
ity found that ~26% women with a history of GDM and a 
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type 2 diabetes genetic risk score in the highest quartile had 
developed diabetes at follow-up compared with ~23% of women 
in the lowest genetic risk score quartile16. The GSs in this 
study were not analysed for their association with incident 
T2D in the HAPO Follow-Up Study, but this would be use-
ful to establish and make direct comparisons with the results 
of this work in the future
In the longer-term, although using the lower FPG threshold 
from the WHO 2013 criteria for identifying GDM will result 
in more cases diagnosed, these women will be an important 
target for long-term follow-up. It is not known whether life-
style interventions such as guided diet and exercise programmes 
could modify risk of progressing to type 2 diabetes in women 
with a history of GDM and a high genetic risk. A study of 
1,744 white women suggested that risk of developing type 2 
diabetes after a pregnancy affected by GDM was greatest in 
women with a high genetic risk score and poor diet16. On the 
other hand, while the Diabetes Prevention Program (DPP)50 
trial found that lifestyle intervention or metformin treatment 
reduced risk of progression to type 2 diabetes in women with 
impaired glucose tolerance and a history of GDM (accord-
ing to relevant criteria at time of diagnosis), a genetic risk score 
for type 2 diabetes did not influence treatment response51. 
Neither of these studies included women specifically diag-
nosed by WHO 2013 criteria, but it is clear from this work and 
that of the HAPO Follow-Up Study that these women would 
benefit from monitoring after pregnancy and should be con-
sidered for targeted lifestyle interventions in public health 
policies focussing on prevention of type 2 diabetes in 
adults.
There are limitations of this study that are important to con-
sider. The small number of cases of GDM included has been 
mentioned and this could have meant that the study was 
underpowered to show clear differences in T2D GS 
between the different diagnostic categories. We also studied 
women from two different studies, where there were notable 
differences in clinical characteristics, even for women with-
out GDM. Additionally, the FPG and T2D GS were consistently 
higher in DIP than in HAPO. This is likely to reflect differ-
ences in SNPs used to generate the genetic scores and possi-
bly a slightly higher genetic disposition to a raised FPG and 
type 2 diabetes in DIP. Meta-analysis would have improved 
power, but was not appropriate due to these differing aspects of 
each study. However, there were remarkably similar patterns 
for the genetic score associations amongst the different diag-
nostic groups in both studies. The results of these analyses 
are therefore likely to be applicable to women of European 
ancestry, but further larger-scale studies, including analysis of 
women with diverse ancestry, will be needed to confirm the 
associations identified in this study
In conclusion, women diagnosed with GDM according to the 
newest WHO 2013 criteria, regardless of how the diagnosis is 
met, have a higher genetic risk for type 2 diabetes compared 
with women without GDM. Overall, the criteria identify an 
important group of women at risk for adverse pregnancy out-
comes as well as a higher risk for developing future type 2 
diabetes8, which can partly be explained by genetic 
predisposition. In addition, this study has added to the literature 
confirming genetic predisposition to type 2 diabetes in women 
with GDM and supports the call for considering GDM as a 




Data is not freely available due to it consisting of potentially 
identifiable information, and as such is held securely to protect 
the interests of research participants in line with the guidance 
from the relevant ethics committees. However, the ethics com-
mittees will allow data analysed and generated in this study to be 
available to researchers through open collaboration. For access 
to the data used in this study please contact Dr Rachel Freathy 
(r.freathy@exeter.ac.uk) and Professor William Lowe Jr (wlowe@
northwestern.edu) in relation to HAPO and Dr Rachel Freathy 
and Professor Fidelma Dunne (fidelma.dunne@nuigalway.ie) 
in relation to Atlantic DIP. Requests will be reviewed as soon 
as possible on receipt and will be facilitated with an agreement 
to ensure that data is transferred and held securely and results 
of new analyses shared with the relevant study investigators. 
The websites describing the studies and other data available 
are https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.
cgi?study_id=phs000096.v4.p1 for HAPO and http://atlanticdipire-
land.com/ for Atlantic DIP. 
Extended data
Figshare: Extended data Wellcome Open Research 16097.pdf. 
https://doi.org/10.6084/m9.figshare.14180033 
The file contains an extended data table with sensitivity analy-
ses adjusting the genetic scores for maternal pre-pregnancy 
BMI and age and a figure with a directed acyclic graph 
(DAG) showing how the relationships between the genetic 
scores and GDM diagnostic category are not driven by maternal 
pre-pregnancy BMI or age.
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Hughes et al. derived a fasting plasma glucose (FPG) as well as a type 2 diabetes (T2D) genetic risk 
scores (GS) in participants from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) and 
Atlantic Diabetes in Pregnancy (DIP) studies. Pregnant women were assigned to gestational 
diabetes (GDM) cases or control groups based on their 75g oral glucose tolerance test results 
using WHO's 2013 criteria. Four different subgroups of cases were devised depending on whether 
participants exceeded the diagnosis threshold for fasting, 1h-, 2h-glucose measures, or a 
combination of these. The authors show that FPG GS was lower in GDM controls compared to 
GDM cases. This association was the strongest when comparing women with a FPG ≥5.1 mmol/L 
only (1-hour glucose <10 mmol/L and 2-hour glucose <8.5 mmol/L) vs. controls. T2D GS was also 
lower in GDM controls compared to cases. 
I concur with all the comments from my fellow Reviewers (1 and 2) on this 2nd version of the 
manuscript. 
 
In addition, I have the following comments/suggestions:




Table 3: describe the mean and SD of the two GSs in controls as well as in each case group. 
 
○
All non-significant results in relation to GS and GDM associations (results shown in Figure 3): 
There seems to be a big issue with the small samples size in each case group and hence, 
large SEs. Non-significant results (or results that do not pass multiple testing) are likely due 
to a lack of statistical power. Similarly, I do not agree with statement (P9 - discussion):” the 
observation that the FPG GS was not higher in women diagnosed with GDM due to a 2-hour 
glucose ≥8.5 mmol/L alone was expected”. The authors could (and should) meta-analyze 
results from HAPO and DIP to increase their power. Given the differences between the two 
○
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studies, adjustments for age and BMI should be considered to reduce between study 
heterogeneity.
Other Minor Modifications:
There is no mention in the methods about how LD was estimated in UK Biobank (data 
version, samples selection, software) 
 
○
Table 4: please remove all the mmol/L within the table to facilitate reading, (units can be 
mentioned in the table’s headers or in the legend). 
 
○
Page 9: under “Women diagnosed with GDM by fasting, 1-hour or 2-hour criteria have a 
higher T2D GS than controls”, please refer to Figure 3B instead of Figure 2B. 
 
○
The fact that all weights of T2D GS SNPs were derived from Voigt et al 2010, and that all 
weights for all FPG GS SNPs were derived from Dupuis et al. 2010 should be mentioned in 
the methods section under “Generating a genetic score for FPG and type 2 diabetes” (in 
addition to legends of table 1 and 2) to avoid any confusion with the last column of Table 2.
○
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Genetics and genomics of complex cardio-metabolic traits
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 08 Mar 2021
Alice Hughes, University of Exeter, Exeter, UK 
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We would like to thank reviewer 3 for their detailed comments on version 2 of the 
manuscript. We have addressed their points in turn below: 
 
1. Tables 1 and 2: Please specify the effect/other allele, effect allele frequency, and 
beta of the proxy SNPs. 
We have provided the effect/other alleles, EAF and beta for the proxy SNPs in the Tables 1 
and 2 as requested. We used the same beta value for proxy SNPs and have clarified this in 
the table footnote. Thank you for alerting us to this. 
 
2. Table 3: describe the mean and SD of the two GSs in controls as well as in each case 
group. 
We have provided the mean and SD of the GSs to Table 3 as requested. 
 
3. All non-significant results in relation to GS and GDM associations (results shown in 
Figure 3): There seems to be a big issue with the small samples size in each case group 
and hence, large SEs. Non-significant results (or results that do not pass multiple 
testing) are likely due to a lack of statistical power. Similarly, I do not agree with 
statement (P9 - discussion):” the observation that the FPG GS was not higher in women 
diagnosed with GDM due to a 2-hour glucose ≥8.5 mmol/L alone was expected”. The 
authors could (and should) meta-analyze results from HAPO and DIP to increase their 
power. Given the differences between the two studies, adjustments for age and BMI 
should be considered to reduce between study heterogeneity. 
We agree with the reviewer’s comment that the wide confidence intervals and non-
significant P values after adjustment for multiple testing is likely due to the small sample 
sizes and resulting low power. We mentioned the small sample size could lead to less 
distinct associations between the diagnostic categories in the eighth paragraph of the 
discussion, but have clarified this to include the fact that this could be related to low power. 
It now reads: “The small number of cases of GDM included has been mentioned and this 
could have meant that the study was underpowered to show clear differences in T2D GS 
between the different diagnostic categories”. 
 
Regarding the comment on it being expected that there was not a higher FPG GS in 
individuals with a raised 2-hour glucose, we agree that in the context of a small study, that 
this might represent the sample size, rather than a considerably lower genetic 
predisposition to raised fasting glucose. However, we do think it remains the case that 
women who meet the criteria for GDM because of a raised 2-hour glucose alone but not a 
raised fasting glucose will likely have a lower FPG GS than women who meet the criteria 
because of fasting hyperglycaemia, and that was supported by the results in both cohorts. 
We have changed the wording of this to reflect these points to: “Thus, the observation that 
the FPG GS was not higher in women diagnosed with GDM due to a 2-hour glucose ≥8.5 
mmol/L alone was likely because these women did not have fasting hyperglycemia. 
However, larger sample sizes would be needed to confidently rule out differences in FPG GS 
between these groups.” 
 
Meta-analysis of the results from both cohorts would improve power, and we did intend to 
do this when we set-out to complete this work. However, due to the different structures of 
the separate studies (in HAPO a random subset were genotyped, whilst DIP genotyped 
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three women without GDM for every one woman diagnosed with GDM using the clinical 
criteria at the time of recruitment), different SNPs (proxies were used in the HAPO GS, 
please see the Methods section for more details), higher GSs in the DIP cohort and different 
proportions of women in the different diagnostic categories, we felt that meta-analysis 
would not be combining like-for-like. We do think that the similar patterns of association 
support the findings in both studies, but for the reasons mentioned we took the decision 
not to meta-analyse. These reasons are shown in paragraph 8 of the discussion, but we 
agree that a comment making it clear that these were reasons precluding meta-analysis 
should be added and have done so in paragraph 8 of the discussion: “Meta-analysis would 
have improved power, but was not appropriate due to these differing aspects of each 
study”. 
 
4. There is no mention in the methods about how LD was estimated in UK Biobank 
(data version, samples selection, software) 
Thank you for pointing this important detail about LD estimates out. We have added to the 
footnotes of Tables 1 and 2 how LD was calculated. 
 
5. Table 4: please remove all the mmol/L within the table to facilitate reading, (units 
can be mentioned in the table’s headers or in the legend). 
We have edited Table 4 to remove the multiple instances of mmol/L to help make it more 
readable. 
 
6. Page 9: under “Women diagnosed with GDM by fasting, 1-hour or 2-hour criteria 
have a higher T2D GS than controls”, please refer to Figure 3B instead of Figure 2B. 
Thank you for pointing out this typo, we have corrected it accordingly. 
 
7. The fact that all weights of T2D GS SNPs were derived from Voigt et al 2010, and that 
all weights for all FPG GS SNPs were derived from Dupuis et al. 2010 should be 
mentioned in the methods section under “Generating a genetic score for FPG and type 
2 diabetes” (in addition to legends of table 1 and 2) to avoid any confusion with the 
last column of Table 2. 
Thank you for pointing this out. We have added a sentence to that effect in the Methods 
section (please see response 2 to reviewer 1 for more details).  
Competing Interests: We are the authors of the article. We have no other competing 
interests to disclose.
Reviewer Report 07 December 2020
https://doi.org/10.21956/wellcomeopenres.18020.r39654
© 2020 Shaat N. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
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Nael Shaat   
1 Department of Endocrinology, Skåne University Hospital, Malmö, Sweden 
2 Department of Clinical Sciences, Genomics, Diabetes and Endocrinology, Lund University, 
Malmö, Sweden 
Authors have investigated whether the fasting, 1-hour and 2-hour glucose thresholds from the 
WHO 2013 criteria for GDM have different genetic susceptibility to raised fasting glucose and type 
2 diabetes in women from 2 cohorts, the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) 
and Atlantic Diabetes in Pregnancy (DIP) studies. For this purpose, they used genetic scores for 
fasting plasma glucose (FPG GS) and type 2 diabetes (T2D GS). The main findings were that the 
mean FPG GS and mean T2D GS were higher in women with only a FPG ≥5.1 mmol/L (or 
combined with 1- or 2-h glucose) than in controls. In addition, mean T2D GS in women with a raised 
FPG alone or with either a raised 1-hour or 2-hour glucose was higher than controls. Authors 
concluded that women with a history of GDM have a higher risk of type 2 diabetes in later-life and 
the risk differs according to how the diagnosis of GDM is met.  
 
The paper is interesting. Many questions have already been raised by the other reviewer. 
 
I have 2 comments:
The authors should mention the statistical power of the study. 
 
1. 
I agree with the other reviewer that the analyses should be adjusted for BMI even if the 
authors have excluded SNPs associated with BMI.
2. 
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Gestational diabetes.
I confirm that I have read this submission and believe that I have an appropriate level of 
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expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 08 Mar 2021
Alice Hughes, University of Exeter, Exeter, UK 
We would like to thank reviewer 2 for their time in helping to improve the manuscript. We 
have addressed their two points as follows: 
 
1. The authors should mention the statistical power of the study. The expected size of 
any genetic score difference between the case and control groups was unknown. However, 
as an indicative power calculation, our sample of N=2,628 HAPO and N=1,084 DIP 
participants both provided 100% power to detect associations between fasting glucose 
levels and the fasting glucose GS at alpha=0.002, assuming the GS explains 6% variance in 
glucose levels, which was estimated in 849 pregnant individuals without diabetes in an 
external study (Exeter Family Study of Childhood Health (EFSOCH)). We have added this 
information to the Methods under the subheading “Analysis of associations between FPG 
GS or T2D GS with glucose levels and GDM.” of the “Statistical analyses” section. 
 
2. I agree with the other reviewer that the analyses should be adjusted for BMI even if 
the authors have excluded SNPs associated with BMI. 
We have addressed adjustments for BMI in response to point number 3 of reviewer 1.  
Competing Interests: We are the authors of the article. We have no other competing 
interests to disclose.
Reviewer Report 12 November 2020
https://doi.org/10.21956/wellcomeopenres.18020.r41234
© 2020 Kawai V. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Vivian K. Kawai  
Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of 
Medicine, Nashville, TN, USA 
I have the following comments for the reviewed manuscript:
SNPs for FPG risk score in Table 1 comes from Dupuis et al., 2010 study, which is OK since 
this is probably the largest GWAS for fasting glucose in individuals of European ancestry. 
 
1. 
However, table 2 shows that selected T2D variants came from different studies and 
populations. Effect estimates depend largely on the sample size and the allele frequency of 
the variant in a population, as well as the impact of a variant in specific population 
2. 
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ancestries. Thus, the authors need to comment how this approach could have affect their 
results and why they select this approach over using a non-weighted GRS or using only 
estimates from the largest study in European ancestry regardless of the p-value reported. 
An alternative approach is to use one of the cohort to define the estimates for each variant 
and then use this estimates in the second cohort to calculate the GRS. 
 
The authors argue that BMI is unlikely to explain the association observed between GDM 
and the risk scores because the variants included into the GRS has no effect on BMI. They 
also say that adjusting for BMI has the potential to bias estimates since patients with higher 
risk scores are likely to developed GDM at lower BMI, which is true. However, confounding 
is a major problem in genetic studies and with the data shown, we cannot rule out that BMI 
is a major driven of the results, which undermines the study.  A sensitivity analysis including 
pre-pregnancy BMI and maternal age is recommended as well as a discussion of how 
including BMI in the analysis may affect the estimates. 
 
3. 
Although this was not the scope of the study, the authors should add a short comment why 
the performance of these GRS for T2D in the HAPO and DIP cohort was not studied, 
particularly when they mentioned that women in HAPO cohort with GDM had higher risk for 




Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: risk assessment
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
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Author Response 08 Mar 2021
Alice Hughes, University of Exeter, Exeter, UK 
We would like to thank reviewer 1 for reviewing the second version of the manuscript, 
having already commented on the first version. We have made changes to improve the 
manuscript based on the new comments and have addressed them below: 
 
1. SNPs for FPG risk score in Table 1 comes from Dupuis et al., 2010 study, which is OK 
since this is probably the largest GWAS for fasting glucose in individuals of European 
ancestry.Yes, the SNPs and effect size estimates part of the FPG genetic score come from 
one study (Dupuis et al.) 
 
2. However, table 2 shows that selected T2D variants came from different studies and 
populations. Effect estimates depend largely on the sample size and the allele 
frequency of the variant in a population, as well as the impact of a variant in specific 
population ancestries. Thus, the authors need to comment how this approach could 
have affect their results and why they select this approach over using a non-weighted 
GRS or using only estimates from the largest study in European ancestry regardless of 
the p-value reported. An alternative approach is to use one of the cohort to define the 
estimates for each variant and then use this estimates in the second cohort to 
calculate the GRS. 
We did not use effect size estimates from different studies. The effect sizes were all derived 
from one GWAS (Voight et al., which was the biggest and most recently available study at 
the time of genotyping). This is shown by the superscript “c” in the “Beta” column. The 
studies in the last column refer to where the SNP was originally identified. Reviewer 3 
picked up on this being unclear and we have taken their advice to include a sentence under 
“Generating a genetic score for FPG and type 2 diabetes” in the Methods section that reads: 
“All weights for the FPG GS and T2D GS were taken from Dupuis et al.9 and Voight et al.26, 
respectively. 
 
3. The authors argue that BMI is unlikely to explain the association observed between 
GDM and the risk scores because the variants included into the GRS has no effect on 
BMI. They also say that adjusting for BMI has the potential to bias estimates since 
patients with higher risk scores are likely to developed GDM at lower BMI, which is 
true. However, confounding is a major problem in genetic studies and with the data 
shown, we cannot rule out that BMI is a major driven of the results, which undermines 
the study.  A sensitivity analysis including pre-pregnancy BMI and maternal age is 
recommended as well as a discussion of how including BMI in the analysis may affect 
the estimates. 
BMI may confound genetic estimates due to collider bias, as we stated in our previous 
response. We would not expect the relationships between GS and GDM diagnosis to change 
according to maternal BMI and age as the SNPs are not causally associated with higher BMI 
or age. The directed acyclic graph (DAG, found in Extended data file: 
https://doi.org/10.6084/m9.figshare.14180033) illustrates this. 
 
However, since all reviewers have requested it, we have performed analyses adjusted for 
maternal pre-pregnancy BMI and age (where available) and present the adjusted GS means 
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and 95% confidence intervals for each GDM diagnostic criteria and controls in an Extended 
Data table which can be found at the following link: 
https://doi.org/10.6084/m9.figshare.14180033 
 
The estimates and associations are very similar to those shown in the main manuscript (see 
Figure 3; to aid comparison we have added a column in the Extended data table with the 
unadjusted values). Since BMI and maternal age were not available in all participants (93% 
of HAPO participants and 51% of DIP participants), the sample size for the adjusted analyses 
was smaller and there was a corresponding attenuation of the strength of associations (as 
shown by wider confidence intervals). However, as can be seen by comparing the adjusted 
and non-adjusted GSs, the estimates were within the 95% CI of the non-adjusted 
associations, indicating that they were consistent between the adjusted and non-adjusted 
analyses. We would prefer not to include this data in the main manuscript for the reasons 
discussed above and in our previous response, but we have included the sentences 
“sensitivity analyses adjusted for maternal BMI and age did not materially alter the GS 
relationships (Extended data Tables 1A and 1B)” and “As with the FPG GS, sensitivity 
analyses adjusted for maternal BMI and age did not materially affect the associations seen 
(Extended data Tables 1A and 1B).” in the “Women diagnosed with GDM by fasting glucose 
criteria have a higher FPG GS” and “Women diagnosed with GDM by fasting, 1-hour and 2-
hour criteria have a higher T2D GS than controls” sections of the results, respectively. 
 
4. Although this was not the scope of the study, the authors should add a short 
comment why the performance of these GRS for T2D in the HAPO and DIP cohort was 
not studied, particularly when they mentioned that women in HAPO cohort with GDM 
had higher risk for T2D 10 to14 years after pregnancy. This is a question that probably 
every reader would have. 
The individuals genotyped in this study do not completely crossover with individuals 
included in the HAPO Follow-Up Study and since the follow-up time has been short so far, 
we are unlikely to have the power to study the performance of the T2D score with incident 
T2D in this cohort, although this is something that would be valuable to do in the future. We 
agree that a comment on this would be helpful and have added the following sentence to 
the discussion at the end of the sixth paragraph “The GSs in this study were not analysed for 
their association with incident T2D in the HAPO Follow-Up Study, but this would be useful to 
establish and make direct comparisons with the results of this work in the future”.  
Competing Interests: We are the authors of the article. We have no other competing 
interests to disclose.
Version 1
Reviewer Report 25 September 2020
https://doi.org/10.21956/wellcomeopenres.17665.r40254
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© 2020 Kawai V. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Vivian K. Kawai  
Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of 
Medicine, Nashville, TN, USA 
The manuscript by Hughes A.E. and collaborators titled: All thresholds of maternal hyperglycaemia 
for the WHO 2013 criteria for gestational diabetes identify women with a higher genetic risk for 
type 2 diabetes” test the hypothesis that each diagnosed criteria have different genetic risk using a 
FPGGS and a T2D GS. 
 
I have the following comments:
Please clarify what is the objective of the study and the clinical utility. 
 
1. 
Previous studies have shown the limited utility GRS for T2 (and likely FPG) in the detection of 
women at risk for GDM, suggesting that either other genetic factors are the main driver of 
GDM or environmental exposures. The authors did not provide a convincing explanation in 
their discussion of the relevance of their findings. 
 
2. 
Having an increase genetic risk for T2D or fasting hyperglycemia is irrelevant if the authors 
cannot show what are the clinical implications of this genetic susceptibility. It is known that 
women with GDM are at higher risk for developing T2D in the future, but the real question 
is whether a high genetic susceptibility or other clinical factors are the main drivers of this 
risk in women who already experienced GDM. 
 
3. 
A major drawback of using GS is that they cannot provide mechanistic insights, so it is 




Please provide a more comprehensive explanation for the GS calculation. 
 
5. 




Pre-pregnancy BMI and maternal age are well known risk factors for GDM. I suggest 
supporting the statement that the association seen between the GS and the different 
diagnostic criteria are not driven by BMI with data. We cannot assume that variants have 
the same impact in BMI variability in non-pregnant and pregnant populations. 
 
7. 




Is the work clearly and accurately presented and does it cite the current literature?
Partly
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Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
No
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: risk assessment
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to state that I do not consider it to be of an acceptable scientific standard, for 
reasons outlined above.
Author Response 13 Oct 2020
Alice Hughes, University of Exeter, Exeter, UK 
We thank the reviewer for their constructive comments on this work. With the help of these 
comments we have taken the opportunity to improve the manuscript. We have addressed 
their comments in turn below and updated the manuscript accordingly (Version 2). 
 
1. Please clarify what is the objective of the study and the clinical utility.  
 
Thank you for prompting us to clarify the message of the paper by stating the objective of 
the study. The objective of the study was to investigate whether there was a difference in 
genetic risk for fasting hyperglycaemia and type 2 diabetes according to the different 
diagnostic thresholds of glucose tolerance as part of the WHO 2013 criteria for gestational 
diabetes (GDM). We originally stated this in the form of a hypothesis to test in the last 
paragraph of the introduction, but we have updated the introduction to refocus it as an 
objective of the study instead (paragraph 4 of the “Introduction” section). 
In relation to the clinical utility of the study there are several points to consider. The 
thresholds for fasting, 1-hour and 2-hour glucose in the WHO 2013 criteria were chosen 
based on their Obstetric risks (i.e. primary caesarean section, large for gestational age baby, 
HAPO study reference: https://doi.org/10.1056/NEJMoa0707943). Although it is well known 
that women with a history of GDM have a higher risk of type 2 diabetes in later-life, it is not 
known if this differs according to how the diagnosis of GDM is met, and whether this may 
partly reflect underlying predisposing genetic factors. As expected, we observed a higher 
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genetic risk for fasting hyperglycaemia in women who had a met the fasting plasma glucose 
criteria (>5.1 mmol/L). We observed a higher genetic risk for type 2 diabetes across all 
diagnostic categories. Therefore, these criteria identify an important group of women with a 
genetic risk for type 2 diabetes. This is important for the clinical community to be aware of, 
since there are many different criteria for GDM used across the world which utilise different 
criteria (for example, in the United Kingdom the fasting glucose cut-off is 5.6 mmol/L and in 
Denmark a fasting glucose is not included). Our findings support the findings of the HAPO 
Follow-Up Study, which showed women diagnosed with GDM according to the WHO 2013 
criteria had higher rates of disorders of glucose metabolism 10 years later (Reference: 
https://doi.org/10.1001/jama.2018.11628). The genetic risk is of particular interest for 
women who meet the criteria for GDM due to a high 2-hour glucose, as we did not observe 
a significantly higher BMI in this group of women. Therefore, if they had not been identified 
as having GDM, these women may not necessarily be considered a high-risk group who 
would require monitoring and follow-up (e.g. with an annual HbA1c). We have added to the 
discussion to emphasise the potential implications for long-term follow-up (paragraph 6, 
“Discussion and conclusion” section). 
Of course, it is not known whether preventative lifestyle interventions could modify this 
genetic risk; we touch on this in the discussion in relation women with a history of GDM in 
the Diabetes Prevention Program (DPP) trial (Reference: https://dx.doi.org/10.2337%2Fdc13-
0700). A recent study suggested that a genetic score for type 2 diabetes was more strongly 
associated with developing type 2 diabetes in women with a history of GDM and a poor diet 
(Reference: https://dx.doi.org/10.1136%2Fbmjdrc-2019-000850). But, they also point out 
that the relationship between the T2D genetic risk score and incident type 2 diabetes was 
modest. We have added to this area of the discussion to provide a more balanced 
discussion on the potential implications of a high genetic risk for type 2 diabetes, 
emphasising the uncertainty of whether the genetic risk could be of benefit in targeting 
public health interventions in relation to post-GDM care (paragraphs 6 and 7). 
 
2. Previous studies have shown the limited utility GRS for T2 (and likely FPG) in the 
detection of women at risk for GDM, suggesting that either other genetic factors are 
the main driver of GDM or environmental exposures. The authors did not provide a 
convincing explanation in their discussion of the relevance of their findings. 
 
We agree that the genetic risk for fasting hyperglycaemia and type 2 diabetes will only 
explain a portion of risk for GDM. The genetic risk will not explain risks associated with BMI, 
maternal age, parity and socioeconomic deprivation. In addition, these genetic scores will 
not explain the higher risks for GDM seen in women of African and South Asian heritage, for 
example. Whilst this study did not aim to assess the power of the genetic scores to diagnose 
or predict GDM, we have added to the discussion taking into account these considerations 
and referencing studies that have focussed on this as a new paragraph in the discussion 
(paragraph 5 of “Discussion and conclusion” section).  
 
3. Having an increase genetic risk for T2D or fasting hyperglycemia is irrelevant if the 
authors cannot show what are the clinical implications of this genetic susceptibility. It 
is known that women with GDM are at higher risk for developing T2D in the future, 
but the real question is whether a high genetic susceptibility or other clinical factors 
are the main drivers of this risk in women who already experienced GDM. 
 
Page 27 of 29
Wellcome Open Research 2021, 5:175 Last updated: 19 APR 2021
 
We have partially responded to the clinical implications in response to comment 1 and point 
to the updated version of the discussion. Similar to comment number 2, we agree that 
genetic risk is likely to explain only a portion of risk for type 2 diabetes and we have added 
to the discussion to emphasise the importance of other factors (please see paragraph 6 of 
the “Discussion and conclusion” section and the response to comment 1 above). However, 
we also believe that genetic risk for type 2 diabetes and fasting hyperglycaemia are likely to 
explain part of the relationship between GDM and type 2 diabetes in later-life. We discuss 
this in more detail in paragraphs 4 and 6 of the “Discussion and conclusion” section. 
  
4. A major drawback of using GS is that they cannot provide mechanistic insights, so it 
is unclear how the use of GS for T2D and FPG for GDM can provide any relevant 
information in GDM. 
 
We believe that genetic scores provide important insights into the biology of GDM. For 
example, the risk loci included in the scores have been implicated in beta cell function, 
proinsulin secretion and impaired insulin action secondary to unfavourable metabolic 
patterns of adiposity and liver lipid metabolism (References: 
https://doi.org/10.1371/journal.pmed.1002654 and https://doi.org/10.1038/s41588-018-
0084-1). The relevance of this to GDM was underlined in a recent paper by Powe et al. 
(Reference: https://doi.org/10.2337/db18-0203), which showed associations between 
genetic risk scores for fasting glucose, fasting insulin, and insulin secretion and sensitivity 
with GDM. In particular, they also observed strong associations between a fasting glucose 
GS and fasting glucose in pregnancy, similar to the associations seen outside of pregnancy, 
emphasising an important shared genetic predisposition. We did not seek to repeat the 
biological relevance of these associations demonstrated in this paper in our work, but 
rather show that there is a higher genetic risk for type 2 diabetes associated with the 
different measures of glucose tolerance in the WHO 2013 criteria for GDM. However, we 
agree that a discussion considering the likely underlying biology of genetic scores in 
relation to type 2 diabetes and GDM will help add to the context of the paper and have 
included a new paragraph in relation to this in the discussion (paragraph 4). 
  
5. Please provide a more comprehensive explanation for the GS calculation. 
 
We have provided a description of the genetic score (GS) calculation in the Methods section 
under the heading titled “Generating a genetic score for FPG and type 2 diabetes”. We have 
also included the formula used in Figure 2. We have added a sentence referring to Tables 1 
and 2 which show where the beta (effect size) was obtained for each SNP used in the score 
to clarify this further. 
  
6. What is the definition of European ancestry: self-reported white or was based on 
population stratification analysis. 
 
European ancestry was based on self-reported white ethnicity in both HAPO and DIP. We 
have added this to the Methods section under the heading titled “Study population”. 
  
7. Pre-pregnancy BMI and maternal age are well known risk factors for GDM. I suggest 
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supporting the statement that the association seen between the GS and the different 
diagnostic criteria are not driven by BMI with data. We cannot assume that variants 
have the same impact in BMI variability in non-pregnant and pregnant populations. 
 
The SNPs at the risk loci included in the genetic scores influence glycaemic traits 
independent of BMI. We did not include SNPs which had their main effect on BMI (e.g. FTO). 
As BMI is not on the causal pathway between the genetic score and the outcome (GDM 
diagnostic criterion) it is not necessary to adjust for it in analyses, hence why it is not 
included in the data presented in this paper. Adjusting for BMI also has the potential to bias 
estimates due to collider-stratification bias (Reference: https://doi.org/
10.1093/hmg/ddw433). For example, we observe a paradoxical negative correlation 
between the T2D GS and pre-pregnancy BMI in HAPO (Spearman’s Rho -0.05, P value 0.01). 
This is not a true association and comes about because individuals with a higher genetic risk 
score are more likely to develop type 2 diabetes at a lower BMI than individuals with a lower 
genetic risk score. However, we agree that there are key differences in GDM risk according 
to BMI, which we have shown in the comparison of BMI between the different diagnostic 
criteria in Table 3 summarising the clinical characteristics of the participants in the studies. 
We have expanded on the importance of the role of BMI contributing to risk of type 2 
diabetes and GDM in the discussion (see responses to Comments 1 and 3 and paragraphs 5 
ad 6 of the “Discussion and conclusions” section). 
  
8. Table 4, please confirm that the outcomes follow normal distribution and provide 
results for DIP. 
 
Fasting glucose, 1-hour and 2-hour glucose have a positive skew in both HAPO and DIP 
(hence their presentation of median with IQR in Table 3). A normal distribution of outcomes 
is not a pre-requisite for linear regression models (Reference: 
https://doi.org/10.1017/CBO9780511790942), so we do not think this is of concern for this 
analysis, but we are happy to supply additional information if the reviewer would like this. 
We have now included a second part to the table with the associations in DIP (which had a 
similar pattern of associations to HAPO), but with a cautionary note (footnote b to Table 4) 
that the beta coefficients seen in a case-control study design will not be applicable to a 
general pregnant population due to the relative over-representation of cases of GDM. Now 
we have included these analyses P values for association have been corrected for 24 
comparisons and we have updated the Methods section under the heading “Statistical 
analyses”.  
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